These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 20211017)

  • 21. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
    Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
    Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype.
    Wang X; Chao L; Ma G; Chen L; Zang Y; Sun J
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):271-8. PubMed ID: 20401669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer.
    Wu J; Zong Y; Fei X; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
    PLoS One; 2014; 9(8):e98673. PubMed ID: 25153161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell division cycle proteinising prognostic biomarker of breast cancer.
    Cheng L; Huang YZ; Chen WX; Shi L; Li Z; Zhang X; Dai XY; Wei JF; Ding Q
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32285914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDAC6 expression is correlated with better survival in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Sugiura H; Omoto Y; Ando Y; Mita K; Hamaguchi M; Hayashi S; Iwase H
    Clin Cancer Res; 2004 Oct; 10(20):6962-8. PubMed ID: 15501975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
    Lee YF; Miller LD; Chan XB; Black MA; Pang B; Ong CW; Salto-Tellez M; Liu ET; Desai KV
    Breast Cancer Res; 2012 May; 14(3):R85. PubMed ID: 22621393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
    Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
    J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer.
    Fu DY; Tan HS; Wei JL; Zhu CR; Jiang JX; Zhu YX; Cai FL; Chong MH; Ren CL
    Tumour Biol; 2015 Sep; 36(10):8025-34. PubMed ID: 25971583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
    Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
    Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer.
    Rosin G; Hannelius U; Lindström L; Hall P; Bergh J; Hartman J; Kere J
    BMC Cancer; 2012 Feb; 12():79. PubMed ID: 22375924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RHAMM splice variants confer radiosensitivity in human breast cancer cell lines.
    Schütze A; Vogeley C; Gorges T; Twarock S; Butschan J; Babayan A; Klein D; Knauer SK; Metzen E; Müller V; Jendrossek V; Pantel K; Milde-Langosch K; Fischer JW; Röck K
    Oncotarget; 2016 Apr; 7(16):21428-40. PubMed ID: 26870892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dual prognostic role for the TGFβ receptors in human breast cancer.
    Hachim IY; Hachim MY; López-Ozuna VM; Ali S; Lebrun JJ
    Hum Pathol; 2016 Nov; 57():140-151. PubMed ID: 27445263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer.
    Zhang M; Chen H; Wang M; Bai F; Wu K
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32043519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer.
    Yang Y; Qian J; Xiang Y; Chen Y; Qu J
    Oncotarget; 2017 Jan; 8(4):6833-6844. PubMed ID: 28036281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
    Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
    Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
    Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
    Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.